Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Agilent Acquires Seahorse Bioscience and its XF Technology for $235 Million

SANTA CLARA, Calif.—Pharma diagnostics company Agilent Technologies, Inc. (A) inked a $235 million deal to acquire privately-held Seahorse Bioscience to complement its mass spectrometry solutions and expand pharma offerings, the company announced this morning. Agilent said Seahorse’s technology enables researchers to “better understand cell health, function and signaling, and how the cell may be impacted […]

Read More »

Gilead Borrows $10 Billion, Spurring Acquisition Speculation

Foster City, Calif.-based Gilead Sciences, Inc. (GILD) announced Wednesday that it filed to borrow $10 billion in an underwritten, registered public offering. The offering will have six tranches that mature between 2018 and 2046.   The offering is planned to close Sept. 14, 2015 and are rated A- by Standard & Poor’s and A3 by […]

Read More »

Celsion Updates Clinical Trial Data and Slashes 20% of Workforce

Lawrenceville, N.J.-based Celsion Corporation (CLSN) announced today that it completed the integration of its June 2014 acquisition of EGEN, Inc., and as part of the consolidation, had cut 15 to 20 percent of its staff and annual operational costs.   In June 2014, Celsion, which focuses on cancer drug development, acquired Huntsville, Ala.-based EGEN, Inc., […]

Read More »

Concordia Healthcare Snaps Up Rare Disease Drugmaker in $3.5 Billion Deal

Canadian company Concordia Healthcare[2] (CXR.TO[3]), headquartered in Oakville, Ontario, announced[4] today that it is buying Amdipharm Mercury Limited[5] (AMCo) from Cinven[6] for $3.5 billion. Cinven is a European private equity firm. The deal will be a combination of cash, common shares of Concordia, and a performance-based earn-out payable in cash. “This acquisition is a key […]

Read More »

Cipla to acquire 100% of generic businesses in US for $550M

MUMBAI, India, Sept. 3, 2015 /PRNewswire/ — Cipla, a global pharmaceutical company which uses technology and innovation to meet the everyday needs of all patients, today announced that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc. The transaction being subject to certain […]

Read More »

Allergan Shells Out $300 Million+ for SoCal Eye Device Maker AqueSys

DUBLIN and ALISO VIEJO, Calif., Sept. 3, 2015 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will […]

Read More »

Lannett to Acquire UCB’s Kremers Urban Unit

Lannett Company Inc. has agreed to buy UCB SA’s Kremers Urban Pharmaceuticals Inc. for $1.23 billion. The deal, with tax benefits expected to top $100 million, also calls for potential contingency payments under sales and timing thresholds. Lannett said it expects the deal to close in the fourth quarter. Lannett’s shares, up 15% this year, […]

Read More »

Valeant Pharmaceuticals To Acquire Synergetics USA

LAVAL, Quebec , Sept. 2, 2015 /CNW/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its affiliate has entered into a definitive agreement under which Valeant will acquire Synergetics USA, Inc. (SURG) for $6.50 per share in cash. In addition to the upfront cash payment, Synergetics stockholders will receive additional […]

Read More »

Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody

Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments   WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the […]

Read More »

Xerox Expands Pharma Portfolio with Acquisition of inVentiv Patient Access Solutions

NORWALK, Conn. & BURLINGTON, Mass.–(BUSINESS WIRE)–Xerox (NYSE:XRX) and inVentiv Health today announced Xerox’s acquisition of inVentiv Patient Access Solutions (iPAS), an inVentiv Health company. The acquisition will expand Xerox’s pharmacy solutions portfolio with an offering to help pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement hurdles. iPAS serves […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom